Skip links and keyboard navigation

Clinical guidelines

COVID-19 assessment, treatment and management

COVID-19 therapeutic management

Decision Pathway: treatment of mild-to-moderate COVID-19 infection in Adults - Queensland (PDF 232 kB)

Guidelines on the use of COVID-19 therapeutics for treatment or prophylaxis of SARS-CoV-2 in  adults (PDF 1162 kB)

This document has been developed by the Queensland Health COVID-19 Therapeutics Working Group (CTWG) to provide clinicians with guidance in the assessment and management of hospitalised patients with COVID-19. These are living guidelines and will be updated frequently as new evidence emerges. Please refer to the version control table at the end of the document for information concerning updates.

The oral antivirals (molnupiravir and nirmatrelvir + ritonavir) may be prescribed according to the List of Approved Medicine (LAM) criteria as per the  Pharmaceutical Benefits Scheme (PBS) criteria.

From November 2022 the medication access request portal (MARP) will replace the request to access forms emailed to COVID Therapeutics Working Group (CTWG) for QH public hospital facilities only. The paper RTA forms for private hospital facilities will remain unchanged.

Please refer to the MARP user guide on how to access and navigate the portal.

MARP can only be accessed whilst logged into QLD Health network.

COVID-19 medications


Nirmatrelvir plus ritonavir (Paxlovid®)


Tixagevimab plus cilgavimab (Evusheld®)

Tixagevimab plus cilgavimab (Evusheld®) National Medical Stockpile stock is currently available through hospital pharmacies at no cost to eligible patients until 31st December 2022.

The QLD prescribing guidelines outline eligibility criteria, access, dosing and administration.

Use of casirivimab plus imdevimab (Ronapreve®) or sotrovimab (Xevudy®) should be guided by NCCET recommendations.

Note: Prescribing hydroxychloroquine

Under the Medicines and Poisons (Medicines) Regulation 2021, a prescription for hydroxychloroquine is not lawful unless written by an authorised prescriber.

Prescribers are authorised to prescribe hydroxychloroquine if:

  • they are one of the following specialist practitioners: dermatologist, emergency medicine physician, haematologist, immunologist, infectious disease  physician, intensive care physician, nephrologist, paediatrician, rheumatologist, specialist physician in general medicine, a dentist who is a specialist registrant in oral medicine; or
  • they are a medical practitioner or nurse practitioner who is continuing treatment with hydroxychloroquine that was initiated by one of these specialist  practitioners.

Medical practitioners and nurse practitioners who are continuing treatment with hydroxychloroquine must mark the prescription with the words ‘Continuing treatment’.

For information on TGA-approved medicines for COVID-19 please visit the TGA website. Further advice to guide their use in Queensland will be provided soon.

Maternity and neonatal

COVID-19 Guidance for maternity and neonatal services
This site refers to the Maternity and Neonatal Clinical Guidelines page and contains information specific to the care of mothers and babies during the COVID-19 pandemic including flowcharts for neonates of suspected or confirmed COVID-19 mothers, operational frameworks for COVID-19 maternity and neonatal services as well as videos and consumer information.

Paediatric care and advice

Preliminary evidence suggests children have a lower susceptibility to SARS-CoV-2 than adults, play a lesser role in transmission, and have a much lower risk of severe infection.

Children, adolescents, and young adults with underlying medical conditions are an exception, with some studies showing that these patients have an increased likelihood of developing severe disease and complications when infected with SARS-CoV-2. However, these studies do not reflect the epidemiology related to the more recently emerged variants such as the Delta variant and the Omicron variant of concern.

View the COVID-19 in children and adolescents: vaccines, transmission at school and disease outcomes webinar from the Centre for Immunisation Research and Surveillance which provides a summary of COVID-19 in children as well as the benefits of vaccination.

The following resources are designed to support health services and healthcare providers in managing COVID-19 in children:

  • COVID-19 Community Child Health Services Guidance for service provision (PDF 211 kB)
    This document has been developed to support service adaptation by community child and youth health services in Queensland Hospital and Health Services (HHSs) during the COVID-19 Pandemic.
  • Paediatric emergency care during the COVID-19 pandemic
    This Children’s Health Queensland site contains information specific to the emergency care of children during the COVID-19 outbreak including chest imaging guidelines, consensus statements on intubation and respiratory therapies and a paediatric airway checklist.
  • Protecting yourself and the community: mask-wearing video for adolescents
    This video helps Queensland adolescents to understand why wearing a face mask is important. It provides tips for what kind of mask to wear and how to wear it properly. The video is designed for both health professionals and educators who work with high schoolers aged 12 years and above. For more information on COVID-19 and children, visit COVID-19 and your child’s health website.

COVID-19 services guidance and guidelines

Intensive Care

  • Clinical Guidelines - ICU inpatient clearance of COVID-19 infection
    The Statewide Intensive Care Clinical Network in coordination with the Statewide Infectious Clinical Network  have developed clinical guidelines to assist determining when an Intensive Care Unit (ICU) inpatient may be considered cleared of COVID-19 and can be moved from a designated COVID area to a non-COVID area to continue treatment.   The clinical guidelines assist in a consistent approach across Queensland ICUs in determining COVID clearance, and the collection of uniform reporting for statewide and national reporting.
  • Queensland Adaptive Model for the Intensive Care Workforce during COVID-19 (PDF 865 kB)
    This document aims to support HHSs to adapt workforce models in ICUs in response to the COVID-19 pandemic.
  • Queensland Intensive Care Support and Telehealth Program support guide (PDF 256 kB)
    The Queensland Intensive Care Support and Telehealth Program (QICSTeP) was developed as a contingency to mitigate the potential impact of COVID-19 on statewide critical care provision. QICSTeP supports Queensland clinicians in accessing advice from intensive care specialists when managing either critically unwell adult patients or patients deteriorating and at risk of becoming critically unwell. QICSTeP is a phased service consisting of three phases, enabling the service to be escalated and de-escalated in response to the evolving Covid-19 pandemic.


End of life care

Last updated: 13 December 2022